Download PDF
Am J Perinatol 2016; 33(03): 229-235
DOI: 10.1055/s-0035-1571147
Prematurity Special Issue
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tocolysis for Acute Preterm Labor: Where Have We Been, Where Are We Now, and Where are We Going?

Reshama Navathe
1   Department of Obstetrics and Gynecology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania
,
Vincenzo Berghella
1   Department of Obstetrics and Gynecology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

18 November 2015

24 November 2015

Publication Date:
25 January 2016 (online)

    Permissions and Reprints

Abstract

Tocolytics have been used for over 60 years for women with preterm labor, which ultimately can lead to preterm birth (PTB). Diagnosing preterm labor is challenging, but use of objective tests such as transvaginal ultrasound of cervical length assists in the identification of women at the highest risk for PTB. Once preterm labor has been diagnosed, clinicians can choose from a variety of drug classes (cyclooxygenase inhibitors, calcium channel blockers, and betamimetics) to achieve the primary goal of delaying delivery by 48 hours, thereby allowing time for administration of corticosteroids for fetal lung maturity, and if appropriate, starting magnesium sulfate for fetal neuroprotection. Cyclooxygenase inhibitors are the only class of tocolytics proven to decrease PTB < 37 weeks. Knowledge of the safety and effectiveness of these medications is paramount. Several additional agents (e.g., oxytocin receptor antagonists) have significant promise, but further studies are required before these medications can be approved for tocolysis in the United States. As we look into the future of tocolysis, we anticipate that deeper understanding of the complex physiology of preterm labor will allow us to uniquely target different etiologies that lead to the final path resulting in spontaneous preterm delivery.

Keywords

tocolysis - preterm labor - cervical length - cyclooxygenase inhibitors - calcium channel blockers - betamimetics - magnesium sulfate - oxytocin receptor antagonists - nitric oxide donors
 

  • References

  • 1 Hamilton B, Martin J, Osterman M, Curtin S. Division of vital statistics births: Preliminary data for 2014. National Vital Statistics Reports. http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_06.pdf . [Accessed 2015]
    PubMedGoogle Scholar
  • 2 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371 (9606) 75-84
    CrossrefPubMedGoogle Scholar
  • 3 Berghella V. Obstetric evidence-based guidelines. London: CRC Press; 2012
    CrossrefGoogle Scholar
  • 4 Hayes EJ, Paul DA, Stahl GE , et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. Obstet Gynecol 2008; 111 (4) 921-926
    CrossrefPubMedGoogle Scholar
  • 5 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. [Review] Cochrane Database Syst Rev 2006; 19 (3) CD004454
    PubMedGoogle Scholar
  • 6 American College of Obstetricians and Gynecologists; Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 127: management of preterm labor. Obstet Gynecol 2012; 119 (6) 1308-1317
    CrossrefPubMedGoogle Scholar
  • 7 Smith R. Parturition. N Engl J Med 2007; 356 (3) 271-283
    CrossrefPubMedGoogle Scholar
  • 8 López Bernal A. Mechanisms of labour—biochemical aspects. BJOG 2003; 110 (Suppl. 20) 39-45
    PubMedGoogle Scholar
  • 9 Fuchs F, Fuchs AR, Poblete Jr VF, Risk A. Effect of alcohol on threatened premature labor. Am J Obstet Gynecol 1967; 99 (5) 627-637
    CrossrefPubMedGoogle Scholar
  • 10 Mehra P, Raghavan KS, Devi PK , et al. Effect of intravenous alcohol on premature labour. Int J Gynaecol Obstet 1970; 8: 160
    PubMedGoogle Scholar
  • 11 Graff G. Failure to prevent premature labor with ethanol. Am J Obstet Gynecol 1971; 110 (6) 878-880
    CrossrefPubMedGoogle Scholar
  • 12 Watring WG, Benson WL, Wiebe RA, Vaughn DL. Intravenous alcohol—a single blind study in the prevention of premature delivery: a preliminary report. J Reprod Med 1976; 16 (1) 35-38
    PubMedGoogle Scholar
  • 13 Keirse MJ. The history of tocolysis. BJOG 2003; 110 (Suppl. 20) 94-97
    CrossrefPubMedGoogle Scholar
  • 14 Gary CF, Gant N, Leveno K, Gilstrap L, Hauth J, Wenstrom KD. Williams Obstetrics. New York, NY: McGraw-Hill; 2005: 823-829
    Google Scholar
  • 15 Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2014; 2: CD004352
    PubMedGoogle Scholar
  • 16 Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999; 94 (5, Pt 2): 869-877
    CrossrefPubMedGoogle Scholar
  • 17 US Food and Drug Administration. FDA Drug Safety Communication: New Warnings Against Use of Terbutaline to Treat Preterm Labor. Silver Spring, MD: FDA; 2011
    Google Scholar
  • 18 Mizuki J, Tasaka K, Masumoto N, Kasahara K, Miyake A, Tanizawa O. Magnesium sulfate inhibits oxytocin-induced calcium mobilization in human puerperal myometrial cells: possible involvement of intracellular free magnesium concentration. Am J Obstet Gynecol 1993; 169 (1) 134-139
    CrossrefPubMedGoogle Scholar
  • 19 Crowther CA, Brown J, McKinlay CJ, Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014; 8: CD001060
    PubMedGoogle Scholar
  • 20 Terrone DA, Rinehart BK, Kimmel ES, May WL, Larmon JE, Morrison JC. A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis. Am J Obstet Gynecol 2000; 182 (6) 1477-1482
    CrossrefPubMedGoogle Scholar
  • 21 Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226
    CrossrefPubMedGoogle Scholar
  • 22 Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204 (2) 134.e1-134.e20
    CrossrefPubMedGoogle Scholar
  • 23 Mercer BM, Merlino AA ; Society for Maternal-Fetal Medicine. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol 2009; 114 (3) 650-668
    CrossrefPubMedGoogle Scholar
  • 24 Doyle L, Crowther C, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Anesthes Dig 2010; 30 (2) 94-95
    PubMedGoogle Scholar
  • 25 Gomez R, Romero R, Medina L , et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005; 192 (2) 350-359
    CrossrefPubMedGoogle Scholar
  • 26 Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197 (4) 426.e1-426.e7
    CrossrefPubMedGoogle Scholar
  • 27 Gomez R, Romero R, Medina L , et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005; 192 (2) 350-359
    CrossrefPubMedGoogle Scholar
  • 28 Haas DM, Kirkpatrick P, McIntosh JJ, Caldwell DM. Assessing the quality of evidence for preterm labor tocolytic trials. J Matern Fetal Neonatal Med 2012; 25 (9) 1646-1652
    CrossrefPubMedGoogle Scholar
  • 29 Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2012; 12: CD003927
    PubMedGoogle Scholar
  • 30 Lyell DJ, Pullen KM, Mannan J , et al. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. Obstet Gynecol 2008; 112 (6) 1221-1226
    CrossrefPubMedGoogle Scholar
  • 31 Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; 5: CD000940
    PubMedGoogle Scholar
  • 32 Reinebrant HE, Pileggi-Castro C, Romero CL , et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2015; 6: CD001992
    PubMedGoogle Scholar
  • 33 Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med 1984; 12 (1) 25-29
    CrossrefPubMedGoogle Scholar
  • 34 Hammers AL, Sanchez-Ramos L, Kaunitz AM. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. Am J Obstet Gynecol 2015; 212 (4) 505.e1-505.e13
    CrossrefPubMedGoogle Scholar
  • 35 Flenady V, Wojcieszek AM, Papatsonis DN , et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev 2014; 6: CD002255
    PubMedGoogle Scholar
  • 36 Ara I, Banu H. A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh J Obstet Gynaecol 2008; 23 (2) 61-64
    PubMedGoogle Scholar
  • 37 Zhang X, Liu M. Clinical observations on the prevention and treatment of premature labor with nifedipine [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao 2002; 33 (2) 288-290
    PubMedGoogle Scholar
  • 38 Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev 2014; 7: CD006169
    PubMedGoogle Scholar
  • 39 Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006; 108 (4) 986-989
    Google Scholar
  • 40 Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev 2013; 1: CD007235
    PubMedGoogle Scholar
  • 41 Raju TN, Mercer BM, Burchfield DJ, Joseph Jr GF. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists. Obstet Gynecol 2014; 123 (5) 1083-1096
    CrossrefPubMedGoogle Scholar
  • 42 Fanaroff JM, Hascoët JM, Hansen TWR , et al; International Perinatal Collegium (IPC). The ethics and practice of neonatal resuscitation at the limits of viability: an international perspective. Acta Paediatr 2014; 103 (7) 701-708
    PubMedGoogle Scholar
  • 43 Goldenberg RL. The management of preterm labor. Obstet Gynecol 2002; 100 (5, Pt 1) 1020-1037
    CrossrefPubMedGoogle Scholar
  • 44 Korenbrot CC, Aalto LH, Laros Jr RK. The cost effectiveness of stopping preterm labor with beta-adrenergic treatment. N Engl J Med 1984; 310 (11) 691-696
    CrossrefPubMedGoogle Scholar
  • 45 Macones GA, Bader TJ, Asch DA. Optimising maternal-fetal outcomes in preterm labour: a decision analysis. Br J Obstet Gynaecol 1998; 105 (5) 541-550
    CrossrefPubMedGoogle Scholar
  • 46 Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2014; 6: CD004452
    PubMedGoogle Scholar
  • 47 Romero R, Sibai BM, Sanchez-Ramos L , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182 (5) 1173-1183
    CrossrefPubMedGoogle Scholar
  • 48 Conde-Agudelo A, Romero R. Transdermal nitroglycerin for the treatment of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol 2013; 209 (6) 551.e1-551.e18
    CrossrefPubMedGoogle Scholar
  • 49 Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database Syst Rev 2014; 5: CD002860
    PubMedGoogle Scholar
  • 50 Suhag A, Saccone G, Berghella V. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015; 213 (4) 479-487
    CrossrefPubMedGoogle Scholar
  • 51 Saccone G, Suhag A, Berghella V. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015; 213 (1) 16-22
    CrossrefPubMedGoogle Scholar